You can now read 5 articles in a month for free on Read as much as you want anywhere and anytime for just 99¢.

Mass. Mover

Dyax slumps as trial is ended

Continue reading below

Burlington-based Dyax Corp. plunged the most in 11 months after it ended a trial of its leading drug candidate for swelling of the skin caused by blood pressure medicines. The trial was halted because the drug, known as ecallantide, may not be effective, according to a statement from the company. Safety wasn’t a reason for the decision, Dyax said. Dyax said it is assessing options regarding future trials to treat angioedema caused by blood pressure medicines.

Loading comments...
Want each day's news headlines delivered fresh to your
inbox every morning? Just connect with us
in one of the following ways:
Please enter a valid email will never post anything without asking.
Privacy Policy
Subscriber Log In

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of